ストックスクリーナーアプリを入手
82.07
2.52%
-2.12
プレマーケット:
82.10
0.03
+0.04%
Kymera Therapeutics Inc (KYMR) 最新ニュース
Can Kymera Therapeutics Inc. stock deliver consistent earnings growth - Улправда
Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing - marketscreener.com
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 24/7 Wall St.
Why Analysts See Kymera Therapeutics Differently After KT 621 Momentum And Rising Fair Value - Yahoo Finance
RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says - marketscreener.com
RBC Capital Raises Price Target for Kymera Therapeutics (KYMR) | - GuruFocus
Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital - Investing.com Canada
Kymera's eczema drug gets fast track designation in the United States - MSN
Obesity data, Kymera and FDA sentiment survey results — a BioCentury podcast - BioCentury
Kymera gains fast track status for oral candidate KT-621 for eczema - MSN
Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat
Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
BVF Inc. IL Boosts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics director Booth sells $21.7 million in stock By Investing.com - Investing.com Canada
Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock - MarketBeat
Owner Atlas Venture Fund X LP Files To Sell 570 Of Kymera Therapeutics Inc [KYMR] - TradingView — Track All Markets
Kymera Therapeutics Soars on Robust KT-621 Trial Results - timothysykes.com
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera's Eczema Drug Gets Fast Track Designation in the United States - Yahoo Finance
Kymera Therapeutics announces $500M proposed public offering - MSN
Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Mizuho Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise ... - Enidnews.com
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Kymera Therapeutics (NASDAQ: KYMR) raises $692.3M in upsized equity offering - Stock Titan
Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data - Yahoo Finance
Kymera gains Fast Track status for oral candidate KT-621 for eczema - Seeking Alpha
KYMR: Analyst Stephens & Co. Raises Price Target to $110 | KYMR Stock News - GuruFocus
Kymera Therapeutics Says KT-621 Receives FDA Fast Track Designation in Atopic Dermatitis - marketscreener.com
KYMR Stock Rating: Mizuho Raises Price Target to $120 | KYMR Sto - GuruFocus
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis - Investing News Network
Mizuho Raises Price Target on Kymera Therapeutics to $120 From $81, Keeps Outperform Rating - marketscreener.com
Kymera Therapeutics (KYMR) Receives FDA Fast Track for KT-621 in Atopic Dermatitis - GuruFocus
FDA grants fast track designation for Kymera’s oral AD treatment By Investing.com - Investing.com Canada
HC Wainwright Has Positive Estimate for KYMR FY2029 Earnings - MarketBeat
Kymera Therapeutics Granted FDA Fast Track Designation for KT-621 in Atopic Dermatitis Treatment - Quiver Quantitative
Kymera (NASDAQ: KYMR) gets FDA Fast Track for KT-621; Phase 2b AD study ongoing - Stock Titan
Marshall Wace LLP Acquires 67,384 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera (KYMR) jumps to all-time high as eczema treatment results impress - MSN
Norges Bank Invests $1.81 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
Kymera Therapeutics Announces Major Stock Offering - TipRanks
Kymera Therapeutics stock soars 46%. Why investors are excited about its anti-inflammatory drug. - MSN
Kymera Therapeutics raises $602M following positive clinical trial results for lead drug - The Business Journals
Eight biopharmas tap markets for $3.24B in early holiday rally - BioWorld MedTech
JP Morgan Raises Kymera Therapeutics (KYMR) Price Target to $125 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $125.00 at JPMorgan Chase & Co. - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up After Analyst Upgrade - MarketBeat
Kymera Therapeutics stock price target raised to $134 from $84 at H.C. Wainwright - Investing.com UK
Avoiding Lag: Real-Time Signals in (KYMR) Movement - news.stocktradersdaily.com
KYMR Expands Common Stock Offering to $602 Million - GuruFocus
JPMorgan Chase & Co. Buys 160,848 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Prices $602 Million Common Share Offering - marketscreener.com
Morgan Stanley maintains Kymera Therapeutics (KYMR) overweight recommendation - MSN
0.18%
0.62%
大文字化:
|
ボリューム (24 時間):